aMAP评分对慢性肝病患者的预后评价及临床应用的研究进展

Research Progress on Prognosis Evaluation and Clinical Application of aMAP Score in Patients with Chronic Liver Disease

原发性肝癌是世界上最常见的恶性肿瘤之一,据全球癌症统计数据显示,肺癌、肝癌、胃癌、乳腺癌和结肠癌是癌症相关死亡的前五大原因,且肝癌死亡率逐年上升,从2018年的第三高癌症死亡率上升到2020年的第二高。肝细胞肝癌(HCC)占原发性肝癌的85%~90%。目前,尽管抗HBV和抗HCV治疗可以显著降低肝癌的发生风险,但是仍然无法完全避免肝癌的发生。aMAP评分的提出突破了既往肝癌风险评分受种族、病因的限制,且相关指标客观性、计算简单快捷而得到了广泛应用。本文从该项评分模型的提出过程、临床应用及其优缺点等方面对近年来的研究情况进行综述。

Primary liver cancer is one of the most common malignant tumors in the world. According to global cancer statistics, lung cancer, liver cancer, stomach cancer, breast cancer and colon cancer are the top five causes of cancer related deaths, and the mortality rate of liver cancer is increasing year by year, rising from the third highest cancer mortality rate in 2018 to the second highest in 2020. Hepatocellular carcinoma (HCC) accounts for 85%~90% of primary liver cancer. At present, alt-hough anti HBV and anti HCV treatment can significantly reduce the risk of liver cancer, it still cannot completely avoid the occurrence of liver cancer. The proposal of the aMAP score breaks through the limitations of race and etiology in the previous liver cancer risk score, and the related indicators are objective, simple and fast to calculate, which has been widely applied. This article reviews the research progress in recent years from the process of proposing this scoring model, its clinical application, and its advantages and disadvantages.